143 related articles for article (PubMed ID: 38096102)
1. Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer.
Gianoukakis AG; Choe JH; Bowles DW; Brose MS; Wirth LJ; Owonikoko T; Babajanyan S; Worden FP
Eur Thyroid J; 2024 Feb; 13(1):. PubMed ID: 38096102
[TBL] [Abstract][Full Text] [Related]
2. Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).
Brose MS; Smit JWA; Lin CC; Tori M; Bowles DW; Worden F; Shen DH; Huang SM; Tsai HJ; Alevizaki M; Peeters RP; Takahashi S; Rumyantsev P; Guan R; Babajanyan S; Ozgurdal K; Sugitani I; Pitoia F; Lamartina L
Thyroid; 2022 Sep; 32(9):1059-1068. PubMed ID: 35950621
[No Abstract] [Full Text] [Related]
3. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
[No Abstract] [Full Text] [Related]
4. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.
Kish JK; Chatterjee D; Wan Y; Yu HT; Liassou D; Feinberg BA
Adv Ther; 2020 Jun; 37(6):2841-2852. PubMed ID: 32382946
[TBL] [Abstract][Full Text] [Related]
5. Timing of multikinase inhibitor initiation in differentiated thyroid cancer.
Brose MS; Smit J; Lin CC; Pitoia F; Fellous M; DeSanctis Y; Schlumberger M; Tori M; Sugitani I
Endocr Relat Cancer; 2017 May; 24(5):237-242. PubMed ID: 28270435
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
[No Abstract] [Full Text] [Related]
7. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
Brose MS; Nutting CM; Sherman SI; Shong YK; Smit JW; Reike G; Chung J; Kalmus J; Kappeler C; Schlumberger M
BMC Cancer; 2011 Aug; 11():349. PubMed ID: 21834960
[TBL] [Abstract][Full Text] [Related]
8. Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer.
Sacks W; Braunstein GD
Endocr Pract; 2014 Mar; 20(3):263-75. PubMed ID: 24126232
[TBL] [Abstract][Full Text] [Related]
9. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
Capdevila J; Trigo JM; Aller J; Manzano JL; Adrián SG; Llopis CZ; Reig Ò; Bohn U; Cajal TRY; Duran-Poveda M; Astorga BG; López-Alfonso A; Martínez JM; Porras I; Reina JJ; Palacios N; Grande E; Cillán E; Matos I; Grau JJ
Eur J Endocrinol; 2017 Oct; 177(4):309-317. PubMed ID: 28687563
[TBL] [Abstract][Full Text] [Related]
10. Radioactive Iodine in Differentiated Thyroid Carcinoma: A Systematic AGREE II Clinical Practice Guideline Appraisal.
Monos S; Fritz C; Harris J; Romeo D; Ng JJ; Xu K; Cooperberg B; Moreira A; Rajasekaran K
Otolaryngol Head Neck Surg; 2024 Jan; 170(1):20-33. PubMed ID: 37694597
[TBL] [Abstract][Full Text] [Related]
11. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
12. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
13. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
[No Abstract] [Full Text] [Related]
14. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
15. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
16. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
Sacks W; Wong RM; Bresee C; Braunstein GD
Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
[TBL] [Abstract][Full Text] [Related]
17. Radioactive iodine ablation post differentiated thyroid cancer surgery: an analysis of use and impact of the American Thyroid Association guidelines.
Sia Y; Dave RV; Nour D; Miller JA; Skandarajah AR; Tasevski R
ANZ J Surg; 2019 Nov; 89(11):E502-E506. PubMed ID: 31674140
[TBL] [Abstract][Full Text] [Related]
18. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
19. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
20. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
[No Abstract] [Full Text] [Related]
[Next] [New Search]
